Fundraising FoxProteostasis Therapeutics
acquired by Yumanity Therapeutics5 known investors
Find your way into Proteostasis Therapeutics
Sign up to find every way you can get introduced to Proteostasis Therapeutics
- Your email: who you already know at Proteostasis Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Proteostasis Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Acquired by Yumanity Therapeutics December 2020 · $150M (approximately $150 million (reverse merger, per secondary source)) · source ↗
Developing disease-modifying therapeutics for diseases of protein processing, with a lead program in cystic fibrosis.
Investors · 5
Avoro Capital Advisorslisted by Avoro Capital AdvisorsNew York
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M
How we know: F-Prime Capital's portfolio page · Not right? Tell us
Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M
How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Proteostasis Therapeutics do?
- Developing disease-modifying therapeutics for diseases of protein processing, with a lead program in cystic fibrosis.
- Who are Proteostasis Therapeutics's investors?
- Proteostasis Therapeutics's investors include Avoro Capital Advisors, F-Prime Capital, New Enterprise Associates (NEA), Sanofi Ventures, Sofinnova Ventures.
- Who acquired Proteostasis Therapeutics?
- Proteostasis Therapeutics was acquired by Yumanity Therapeutics.